论文部分内容阅读
血管新生是肿瘤生长、转移的重要条件。在导致肿瘤血管新生的因素中,血管内皮生长因子(vascular endothelialgrowth factor,VEGF)被认为是最重要的因素。抑制VEGF的信号转导有可能抑制血管新生,并进一步抑制肿瘤生长。目前有几种新的可能抑制VEGF信号转导的方法,其中包括基因水平上抑制VEGF及VEGF受体(VEGF receptor,VEGFR)的表达、中和血液循环中的VEGF或VEGFR,以及抑制VEGFR的酪氨酸激酶活性以达到抑制其下游的信号转导等。迄今为止,已报道多种针对VEGF抗血管新生的生物及化学制剂,部分已应用于临床,其他制剂正在进行动物试验或临床试验。本文对抑制VEGF信号转导在抗肿瘤治疗中的研究新进展做一综述。
Angiogenesis is an important condition for tumor growth and metastasis. Among the factors leading to tumor angiogenesis, vascular endothelial growth factor (VEGF) is considered as the most important factor. Inhibition of VEGF signaling may inhibit angiogenesis and further inhibit tumor growth. There are several new approaches that may inhibit VEGF signaling including gene expression of VEGF and VEGF receptors (VEGFRs), neutralization of VEGF or VEGFR in blood circulation, and inhibition of VEGFR Kinases activity to inhibit downstream signal transduction and so on. To date, a number of biological and chemical agents targeting VEGF antiangiogenesis have been reported, some of which have been used clinically and others are undergoing animal tests or clinical trials. This article reviews the recent advances in the study of the inhibition of VEGF signaling in antitumor therapy.